1h Free Analyst Time
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Histamine H4 Receptor - Drugs In Development, 2022, outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 4 respectively. Report covers products from therapy areas Dermatology, Ear Nose Throat Disorders, Immunology, Ophthalmology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Age Related Macular Degeneration, Allergic Conjunctivitis, Allergies, Chronic Urticaria Or Hives, Hearing Disorders and Idiopathic Pulmonary Fibrosis.
Furthermore, this report also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
- The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
- Bioprojet SCR
- H4Orphan Pharma
- JW Pharmaceutical Corp
- Leo Pharma AS
- Sensorion SA
- Sosei Group Corp
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
- azasetron - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BPI-7881A - Drug Profile
- Product Description
- Mechanism Of Action
- H4 antagonist - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JWP-1601 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LEO-152020 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize HRH4 for Idiopathic Pulmonary Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
- Product Description
- Mechanism Of Action
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
- Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
- Featured News & Press Releases
- Jun 15, 2022: Sensorion to present at the Inner Ear Disorder Therapeutics Summit in June 2022
- Jun 07, 2022: Sensorion announces approval in France to initiate proof of concept clinical trial of SENS-401 for residual hearing preservation during cochlear implantation
- Mar 17, 2022: Sensorion update on SENS-401
- Feb 03, 2022: Sensorion to present three posters on SENS-401 in Cisplatin ototoxicity models at the association for research in Otolaryngology (ARO) 45th Annual MidWinter Meeting
- Jan 18, 2022: Sensorion's sudden sensorineural hearing loss asset fails Phase II test
- Dec 14, 2021: LEO Pharma initiates a phase 2b dose-ranging clinical trial with an oral H4R antagonist in adult patients with moderate-to-severe atopic dermatitis (AD)
- Oct 27, 2021: Sensorion surpasses enrollment target for SENS-401 in SSNHL, results available in January 2022
- Oct 07, 2021: Sensorion hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021
- Sep 24, 2021: Regulators approve Sensorion’s amendment to phase 2 AUDIBLE-S trial of SENS-401 in sudden sensorineural hearing loss
- Sep 08, 2021: Sensorion and Cochlear to begin first clinical trial of SENS-401 for hearing preservation in combination with Cochlear Implantation
- May 04, 2021: Sensorion to attend three conferences in May 2021 including ASGCT to present a poster and co-chair a scientific session
- Feb 19, 2021: Sensorion presents new preclinical data on on SENS-401 at ARO 2021
- Jan 19, 2021: Sensorion announces preclinical data demonstrating SENS-401’s potential to preserve residual hearing after cochlear implantation
- Jan 05, 2021: Sensorion provides an update on plans and progress in the development of SENS-401 for the prevention of hearing loss
- Jul 16, 2020: Sensorion hosting key opinion leader call with Dr. Michael Hoffer on sudden sensorineural hearing loss and SENS-401 as a Potential Treatment Option on July 23, 2020
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Bioprojet SCR, 2022
- Pipeline by H4Orphan Pharma, 2022
- Pipeline by JW Pharmaceutical Corp, 2022
- Pipeline by Leo Pharma AS, 2022
- Pipeline by Sensorion SA, 2022
- Pipeline by Sosei Group Corp, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bioprojet SCR
- H4Orphan Pharma
- JW Pharmaceutical Corp
- Leo Pharma AS
- Sensorion SA
- Sosei Group Corp
